(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 May 2021 (20.05.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/094830 A3

(51) International Patent Classification:
C07D 487/04 (2006.01) *A61P 27/02* (2006.01)
A61K 31/519 (2006.01)

(21) International Application Number:
PCT/IB2020/000950

(22) International Filing Date:
09 November 2020 (09.11.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10-2019-0143747 11 November 2019 (11.11.2019) KR

(71) Applicant: **ILDONG PHARMACEUTICAL CO., LTD.** [KR/KR]; 2, Baumoe-ro 27-gil, Seocho-gu, Seoul 06752 (KR).

(72) Inventors: **LEE, Yoon-Suk**; 20, Samsung 1-ro 1-gil, Hwaseong-si, Gyeonggi-do 18449 (KR). **KWON, Sung-Wook**; 20, Samsung 1-ro 1-gil, Hwaseong-si, Gyeonggi-do 18449 (KR). **KIM, Kyung-Sun**; 20, Samsung 1-ro 1-gil, Hwaseong-si, Gyeonggi-do 18449 (KR). **KIM, Jeong-Geun**; 20, Samsung 1-ro 1-gil, Hwaseong-si, Gyeonggi-do 18449 (KR). **KIM, Jeong-Ah**; 20, Samsung 1-ro 1-gil, Hwaseong-si, Gyeonggi-do 18449 (KR). **MOON, An-Na**; 20, Samsung 1-ro 1-gil, Hwaseong-si, Gyeonggi-do 18449 (KR). **PARK, Sun-Young**; 20, Samsung 1-ro 1-gil, Hwaseong-si, Gyeonggi-do 18449 (KR). **BAN, Jun-Su**; 20, Samsung 1-ro 1-gil, Hwaseong-si, Gyeonggi-do 18449 (KR). **SONG, Dong-Keun**; 20, Samsung 1-ro 1-gil, Hwaseong-si, Gyeonggi-do 18449 (KR). **JUNG, Ju-Young**; 20, Samsung 1-ro 1-gil, Hwaseong-si, Gyeonggi-do 18449 (KR). **LEE, Soo-Jin**; 20, Samsung 1-ro 1-gil, Hwaseong-si, Gyeonggi-do 18449 (KR).

(54) **Title:** NITROGEN OXIDE-DONATING PDE-5 AND/OR PDE-6 INHIBITOR COMPOUNDS




FIG. 4

(57) **Abstract:** The present disclosure provides phosphodiesterase 5 (PDE-5) and/or phosphodiesterase 6 (PDE-6) inhibitor compounds and compositions including said compounds. In some embodiments, said compounds are nitrogen oxide (NO) donating PDE-5 and/or -6 inhibitor compounds that include a nitrogen oxide-containing donor substituent attached to a benzenesulfonamide group. The compounds can provide dual functionality for increasing protein kinase G (PKG) activity by inhibiting PDE-5 and PDE-6, and/or stimulating guanylate cyclase (sGC) via donation of nitrogen oxide (NO) from the donor substituent of the compound. The present disclosure also provides methods of using said compounds and compositions for inhibiting PDE-5 and/or -6 and increasing activity of protein kinase G (PKG). The compounds and compositions find use in therapeutic applications including in the treatment of a variety of eye diseases. For example, the subject compounds may be used as a therapeutic agent for glaucoma, age-related macular degeneration

WO 2021/094830 A3

[Continued on next page]

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(88) **Date of publication of the international search report:**
24 June 2021 (24.06.2021)

(AMD), diabetic retinopathy (DR), xerophthalmia, cataracts or uveitis.